English

Hongdae Juvelook vs. Juvelook Volume: A Comparative Technical Analysis of Mechanisms, Indications, and Clinical Protocols

nBom Article
Hongdae Juvelook vs. Juvelook Volume: A Comparative Technical Analysis of Mechanisms, Indications, and Clinical Protocols
2026.10.26

Juvelook and Juvelook Volume are US FDA and KFDA (MFDS)-approved autologous collagen boosters combining biodegradable PLA and hyaluronic acid (HA). 

Discover their particle mechanisms, longevity, comparative differences with HA fillers and Sculptra, and essential clinical insights from a medical director.

 

 

Hongdae Juvelook vs. Juvelook Volume
: A Comparative Technical Analysis of Mechanisms, Indications, and Clinical Protocols

 

 

 

What Are Hongdae Juvelook and Juvelook Volume?

 

Juvelook and Juvelook Volume are autologous tissue-regenerating collagen boosters combining biodegradable polymer PLA (polylactide) and hyaluronic acid (HA) to restore skin elasticity, fine lines, enlarged pores, atrophic acne scars, and structural facial volume, approved by the Ministry of Food and Drug Safety (MFDS/KFDA) and the U.S. Food and Drug Administration (FDA). 

 

Official dual vial packaging shot of Juvelook Skin and Juvelook Volume hybrid fillers manufactured by VAIM

 

 

Both formulations are engineered to degrade completely within the body over time without leaving synthetic residue, inducing natural structural remodeling.

 

Based on official Juvelook Product Guidelines and patented porous micro-particle architecture, the product is categorized into two distinct clinical formulations:

 

  • Juvelook (Skin Booster): Formulated with micro-particles measuring 10–30 µm, combining PLA and hyaluronic acid for intradermal injection to treat elasticity loss, superficial rhytids, pore dilatations, atrophic acne scars, and irregular skin texture.

 

  • Juvelook Volume: Formulated with larger micro-particles measuring 30–50 µm to deliver enhanced volumization and structural lifting. 
    It is targeted at deeper anatomical levels (the deep dermis and subcutaneous layer) to treat structural hollows, nasolabial folds, and volume deficiencies.

 

 

What Is the Biological Mechanism of Porous Reticular PLA and HA?

 

The primary mechanism relies on porous reticular micro-particles that sustain autologous neocollagenesis over an extended duration while minimizing the risk of nodule formation.

 

Side-by-side scanning electron microscope (SEM) micrographs showing the spherical outer surface at 2,000x and internal porous reticular cross-section at 1,400x of a PDLLA microsphere.

 

 

  1. HA Hydration and Immediate Stabilization (Step 1): 
    Following injection, the non-crosslinked hyaluronic acid fraction binds interstitial moisture, delivering immediate hydration and soft structural support while facilitating uniform dispersion of PLA micro-particles.

  2. Neocollagenesis via Porous Reticular Scaffolding (Step 2): 
    Host cells migrate into the micro-pores of the PLA particles, activating tissue fibroblasts. 
    This triggers the progressive synthesis of type I and type III collagen without provoking pathological foreign-body reactions.

  3. Complete Biodegradation Without Residue (Step 3): 
    After stimulating localized collagen synthesis, the PLA micro-particles undergo hydrolytic cleavage, breaking down into water and carbon dioxide to be metabolized and excreted, leaving zero permanent foreign material behind.

 

 

How Do Juvelook Formulations Compare to Conventional Injectables?

 

The following matrix compares Juvelook formulations with crosslinked HA fillers, PLLA (Sculptra), and CaHA (Radiesse):

Parameter

Juvelook (Skin)

Juvelook Volume

Crosslinked HA Fillers

Sculptra (PLLA)

Radiesse (CaHA)

Active Ingredients

PLA + Hyaluronic AcidPLA (High Density) + HACrosslinked HA (BDDE)Poly-L-lactic Acid (PLLA)30% CaHA + 70% CMC Gel

Particle Size / Shape

10–30 µm (Porous Reticular)30–50 µm (Porous Reticular)Crosslinked Gel Matrix40–63 µm (Irregular Polygon)25–45 µm (Smooth Sphere)

Primary Mechanism

Dermal ECM RestorationStructural VolumizationPhysical Hydrophilic FillingL-Lactide Immune ResponseCaHA Scaffold Stimulation

Target Depth

Papillary to Reticular DermisDeep Dermis to SubcutaneousMid Dermis to SubcutaneousSubcutaneous / PeriostealSubdermal / Supraperiosteal

Onset of Visible Results

3–4 weeks4–6 weeksImmediate (Day 0)6–8 weeksImmediate (Gel) + 8–12 weeks

Clinical Longevity

12–16 months18–24 months6–12 monthsUp to 24 months12–18 months

Regulatory Clearance

KFDA / FDA ClearedKFDA / FDA ClearedMFDS / FDA ClearedMFDS / FDA ClearedMFDS / FDA Cleared

 

 

What Are the Standard Stages of the Clinical Treatment Protocol?

 

Clinical injection procedures established in Hongdae follow a standardized four-step medical protocol (Consultation → Anesthesia → Injection → Post-Care):

 

  • Step 1 Consultation: 
    The patient's epidermal thickness, structural volume loss, depth of rhytids, and scar patterns are evaluated to determine the appropriate product type and volume (cc).

 

  • Step 2 Topical Anesthesia: 
    A high-concentration topical anesthetic cream is applied to the target area for 30–40 minutes to minimize procedural discomfort.

 

  • Step 3 Juvelook / Juvelook Volume Administration:

    • Juvelook: Administered intradermally via micro-droplet injection techniques to target fine wrinkles and enlarged pores uniformly.

    • Juvelook Volume: Delivered to deeper subcutaneous planes using a blunt safety cannula to treat hollow regions and deep folds.

 

  • Step 4 Post-Care Finishing: 
    Topical soothing and aseptic post-treatment care are applied to protect the barrier and prevent localized infection.

 

 

Frequently Asked Questions (FAQ)

 

Q1. What level of pain should be expected during the procedure?

A1. On a visual analog scale (VAS) of 0 to 10, patient-reported discomfort averages between 2 and 3. 

The application of topical lidocaine cream during Step 2, along with buffering agents incorporated during formulation preparation, ensures pain and tissue pressure remain minimal.

 

Q2. Can Juvelook or Juvelook Volume be dissolved with hyaluronidase?

A2. While the hyaluronic acid carrier dissolves upon administration of hyaluronidase, the primary PLA micro-particles cannot be dissolved enzymatically.

However, Juvelook utilizes porous spherical micro-particles rather than irregular crystals, resulting in an exceptionally low incidence of nodule formation. 

Proper pre-treatment hydration and correct plane delivery further safeguard against mechanical clumping.

 

Q3. What post-treatment precautions must be observed?

A3. For 72 hours following treatment, patients must avoid high-temperature environments (such as saunas and steam rooms), strenuous exercise, and alcohol consumption to prevent vasodilation and excessive swelling. 

Unlike conventional crystalline PLLA, aggressive post-treatment self-massage (such as the 5-5-5 protocol) is not required and should be avoided to prevent particle displacement; standard gentle cleansing, hydration, and sun protection are sufficient.

 

Official brand logo insignia of MeSOnBOM Clinic Hongdae for aesthetic dermatology and regenerative treatments.

 

This column was written in compliance with medical regulations.
Individual results may vary, and temporary side effects such as bruising, swelling, or tenderness may occur; please consult with a qualified medical professional prior to treatment.

 

 

Author | Dr. Yumin Lee

Medical Institution | MeSOnBOM Clinic

Reservation & Consultation
Monday
Monday
10:00 - 20:00
Tuesday
Tuesday
10:00 - 20:00
Wednesday
Wednesday
Closed
Thursday
Thursday
10:00 - 20:00
Friday
Friday
10:00 - 20:00
Saturday
Saturday
10:00 - 16:30
Sunday
Sunday
10:00 - 16:30
Lunch Break
Lunch Break
14:00 - 15:00
We Operate without lunchtime on Saturdays
TEL : +82-50-7873-0451
Address : 162, Yanghwa-ro, Mapo-gu, Seoul Kakao Friends Flagship Store 7th Floor
Business Registration Number : 766-26-00468
Representative : Yumin Lee
© ⓒ2025. MeSOnBom Clinic. All rights reserved.